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Abstract: Genetic variability in humans can explain many differences in disease risk factors. Polymorphism-related 
studies focus mainly on the single nucleotide polymorphisms (SNPs) of coding regions of the genes. SNPs on DNA 
binding motifs of the promoter region have been less explored. On a recent study of SNPs in patients with non- 
Hodgkin lymphomas we faced the problem of SNP selection from promoter regions and developed a practical me-
thodology for clinical studies. The process consists in identifying SNPs in the coding and promoter regions of the an-
tigen-processing system using the ‘dbSNP’ database. With the ‘HapMap’ program, we select SNPs with frequencies 
>20% in Caucasian populations. For coding regions, we sought biologically and clinically relevant SNPs described 
in the literature. For the promoter regions, we determined their chromosomal location on ‘QiagenSABioscience’ site 
database. The nucleotide sequence of ancestral and variant alleles is available in the ‘dbSNP’. These sequences 
were used in ‘Promoter TESS’ to determine binding differences of transcription factors. Each sequence may have 
affinity to different TFs. Thus, SNP selection on the promoter regions was based in the differences on TF binding 
pattern between the old and the new allele. The potential clinical relevance of the new TFs was also evaluated be-
fore the final selection. With this approach, we found that almost half of the relevant SNP fall within the promoter 
region. In conclusion, we were able to develop a methodology of oriented selection of promoter regions of human 
genes, comparing the TF with affinity to the ancestral allele with the TF to a variant allele. We selected those SNPs 
that change the TF’s affinity to a pattern with functional significance.
Keywords: Genetic polymorphism, SNP, DNA binding motifs, promoter region, coding region, dbSNP, HapMap, 
Promoter TESS
Introduction
The Human Genome Project, an international 
undertaking involving many research labs in 
several countries, published the complete 
sequence of the human genome in 2003. The 
complexity of genetic expression is not only due 
to gene sequence, but also to extensive inter-
actions between DNA, RNA and proteins, and 
to the transcriptional regulation and polymor-
phic variations in human genes, such as SNP 
(single nucleotide polymorphism). To be consid-
ered a polymorphism, the SNP must be present 
in at least 1% of the population. SNPs are not 
considered mutations because often they do 
not change the phenotype significantly, howev-
er they can be responsible for diseases when 
the new amino acid causes even a small altera-
tion in protein function.
The genetic polymorphic variations are current-
ly a major concern because they have been 
associated to multiple human diseases and 
can also explain many of individual differences 
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in behaviour, drug reaction and other biological 
processes. 
Although the main target of polymorphism 
research in humans has been the coding 
regions of genes, the National Human Genome 
Research Institute and its branch ENCODE 
reported recently that 20% of the non-coding 
DNA is functional and involved in gene regula-
tion. It is relevant that 90% of sequence altera-
tions are located outside the coding region and 
maybe associated with diseases [1]. 
The problem of SNP selection led the authors 
to study genetic variants associated with the 
risk of Non-Hodgkin Lymphoma (NHL). These 
cancer studies of SNP polymorphisms have 
been done in genes of multiple systems, such 
as metabolic pathways, biotransformation 
enzymes, DNA repair genes, folate metabolism, 
interleukins and immune function proteins. 
Many of them have been associated with risk 
or prognosis of the disease [2-8]. However, indi-
vidual variability in proteins of immune res- 
ponse as antigen processing and presentation 
may be implicated but were never studied. For 
that purpose the authors tried to develop a 
more accurate method to identify SNPs with 
functional importance in the genes of those 
immune response proteins.
In the context of malignant diseases, the immu-
nological response depends on class-I Major 
Histocompatibility Complex (MHC) and on an 
elaborate enzymatic system required for anti-
gen presentation, including ubiquitin-protea-
some (UB) system and transporter associated 
with antigen processing (TAP). 
When identifying SNP in our target proteins, it 
was easy to locate and select those found in 
the gene coding area, by consulting the rele-
vant biomedical literature. However, the search 
and selection of SNPs on the promoter region 
and on other regulating components raised 
very complex questions that led us to develop 
our own methods described below. The prob-
lem in studying SNPs in these regions is that 
they do not change the protein structure 
because they are not coding regions, but they 
do control transcription. Transcriptional regula-
tion involves proteins and TFs that bind to short 
regulatory sequences, or motifs, in the promot-
er region, also known as transcription factors 
binding site (TFBS). A SNP in these regions can 
change the affinity for the usual TFs and in cer-
tain situations lead to the introduction of new 
ones. Therefore, the question becomes “which 
are now the new TFs for a SNP in the promoter 
region of interest and which TFs have lost their 
affinity”?
This is even more complex given that a TF bind-
ing to DNA motifs does not occur according to a 
digital pattern of all or nothing, but has an ana-
logical, probabilistic pattern [9, 10]. The pres-
ence of a SNP in a promoter region can reduce, 
but not eliminate, the affinity of certain TFs to 
an ideal nucleotide sequence. The probabilistic 
pattern of ligation protein-DNA predicts, for 
example, the affinity of a TF to different TFBS 
with an analogue nucleotide sequence (promis-
cuity) and also, the existence of different TFs 
with affinity for the same sequence (sequence 
degeneration).
Therefore, the goal of this study was to develop 
a method to select SNP in the coding and 
essentially the promoter regions of genes. The 
study of genes involved in antigen processing 
and presentation were the reason to develop 
the new methodology and its practical app- 
lication.
Methods
Computer tools and databases used to select 
SNPs in coding and promoting regions of the 
genes
The method presented here for SNP search 
and selection was developed and subsequently 
applied to a cohort of patients with NHL. We 
had a dual goal: develop a methodology for the 
selection of clinical relevant SNPs in coding 
and promoter sequences of any gene and test 
the practical applicability of the method previ-
ously developed to study the genes that regu-
late the proteins involved in antigen processing 
and presentation.
Protein selection
We used PubMed and Google to find relevant 
literature and identify proteins of the antigen 
processing systems and chose the ones that 
had a confirmed relevant role on human biolo-
gy, according to the study published. A useful 
site was www.genecards.org, part of the Wei- 
zmann Institute of Science and LifeMap that 
describes protein function and gene’s location 
Selection of SNPs in promoter regions
128 Int J Mol Epidemiol Genet 2016;7(3):126-136
in the genome such as chromosome, chromo-
somal band, nucleotide sequence and number 
of nucleotide base on topography of chromo-
some DNA. This site also reports the protein 
expression in different human tissues either, 
normal or neoplastic and gene expression by 
RNA sequencing obtained from Illumina Body 
Map or SAGE (Serial Analysis of Gene Ex- 
pression). The site directed us to other web 
pages such as ‘HapMap’ and ‘QIAGEN’ which 
describe the phylogenetic and evolutionary 
relationship of genes, description of SNPs, their 
nucleotide sequences and frequency in the 
populations studied [11].
SNP selection in coding regions
Information about SNPs obtained from any 
data source can be used directly for further 
studies regarding the coding regions of the 
genes. We considered the results from previ-
ous biomedical studies published in English. 
Preferentially, but not exclusively, we selected 
SNPs that have a frequency of 20% or higher 
among Caucasian populations. This informa-
tion can be obtained in ‘HapMap’, provided by 
the NIH, at www.hapmap.ncbi.nlm.nih.gov. For 
SNPs with lower frequencies, we selected those 
particularly prevalent in the Iberian population, 
information obtained from “1000 Genomes” in 
the same site of ‘dbSNP’ and ‘HapMap’. 
Application of this simple direct selection can 
be much less useful for promoter regions and 
thus a new methodological strategy was re- 
quired. 
SNP selection in promoter regions
The search for SNPs in the promoter regions of 
the proteins of interest turned out to be com-
plex and required several steps: First, we deter-
mined the gene location in the chromosome 
and its promoter using Qiagen SABioscience 
database at www.sabioscience.com/chipqp-
crsearch.phap?app=TFBS. This database uses 
TRANSFAC and JASPER recorded information to 
provide chromosomal location, TFs, and their 
binding sites. Then using the chromosomal 
interval containing the gene promoter, we iden-
tified the SNPs available in the ‘HapMap’ 
database.
‘HapMap’ allows human chromosome visual-
ization and permits successive amplifications 
from chromosomal bands to nucleotide sequ- 
ence as well as the SNPs identified along the 
chromosomal locations. Furthermore, ‘Hap- 
Map’ provides the frequency of SNPs in several 
populations groups already studied including 
African sub ethnicities, Native Americans, 
Europeans and Chinese Han ethnicity. Unlike 
the coding regions, we restricted the study to 
the SNPs of promoter regions whose frequency 
on Caucasian populations registered on ‘Hap- 
Map’ were >20%.
For identifying the DNA binding motif sequence 
where SNPs occurred and its chromosomal 
location on the target protein gene, we used 
the powerful database ‘dbSNP’ that provides 
SNPs from diverse species including Homo 
sapiens. They are presented in the middle of a 
nucleotide sequence with approximately 20 
adjacent nucleotides, half of which toward 3’ 
and the other half toward 5’, of the truncated 
base. For each SNP the ancestral allele and the 
new variant sequence were registered.
Afterwards, using the nucleotide sequence 
identified above at ‘dbSNP’ we compared TF 
settings. The affinity of TF for ancestral se- 
quences of TFBS or for the variant TFBS 
induced by SNPs in the promoter regions can 
be obtained using ‘Promoter TESS’ at www.cbil.
upenn.edu/cgi-bin/tess?RQ=WELCOME. 
Finally, part of the information about TFs role in 
infection, inflammation, immunity, neoplasia, 
and aging was obtained through ‘Promoter 
TESS’, but was later expanded and analysed 
using the information provided by ‘GeneCards’ 
and in the literature published on ‘PubMed’ and 
Google.
Practical application of selected SNPs 
DNA collection, genotyping by PCR amplifica-
tion, clinical registry data and statistical analy-
sis will be performed as the next step of this 
project during the practical application of the 
methodology to our target proteins. 
Results
Method development for searching polymor-
phisms and its function in the coding and 
promoter regions of the genes
In this study, we used the genes of proteins of 
antigen processing and presentation systems. 
One of our objectives was to find SNPs with a 
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Table 1. SNPs from coding and promoter regions of selected genes 
from antigen processing/presentation systems
Gene Gene location-pr SNPs-cr SNPs-pr
PSMA6 chr14: 35,741,574-35,771,574 rs12878391 rs1755784
rs1048990 rs10139973
rs17553775
rs1766136
rs7148603
rs1766135
rs2787423
rs1766143
rs1766145
PSMA7 chr20: 60,708,474-60,738,474 rs3746651
rs2281740
rs2057169
PSMB4 chr1: 151,352,041-151,382,041 rs2296840 rs11205209
rs4603 rs310133
PSMB8 chr6: 32,801,816-32,832,712 rs28772340
rs2858892
rs2859112
rs13199787
rs7773407
rs6457644
rs11758312
rs9276490
rs6918223
rs7770024
PSMD7 chr16: 74,310,681-74,340,681 rs17336700
PSMD9 chr12: 122,306,646-122,336,646 rs1043307 rs4759415
rs74421874
rs3825172
rs14259
UBQLN2 chrX: 56,570,072-56,600,072 rs12344615
rs11140213
rs2781003
rs2780995
rs944947
rs2781002
Hsp70 chr5: 132,367,662-132,397,662 rs14355
rs398606
Bag1 chr9: 33,254,761-33,284,761 rs706118
PSMD5 chr9: 123,595,506-123,625,206 rs10760117 rs10985387
rs10739575 rs10818593
rs4641136
rs3802488
rs13299463
rs4307413
B2M chr: 15:44,983,685-45,013,685 rs2255235 rs16958856
rs4349090
potential role in the recon-
naissance and immunologi-
cal response to the Herpes 
virus family on NHL patients 
and in NHL oncogenesis.
Protein selection 
For clinical application of our 
methodology, we selected 22 
proteins from the hundreds 
of proteins that integrate the 
antigen processing UB sys-
tem, TAP protein, ER conjuga-
tion, lysosomal alternative 
pathway, and MHC system. 
First, we only considered pro-
teins that have a role in anti-
gen processing and presen-
tation and, secondly, we only 
included those that have 
demonstrated influence in 
inflammation, antigen pro-
cessing mechanisms, infec-
tious diseases, cancer, and 
aging.
From these 22 proteins, 28 
SNPs in coding region and 26 
of promoter region were 
selected for further study. 
SNP selection was based on 
the following criteria.
Selecting SNPs in coding 
regions
We used ‘dbSNP’ database 
to determine SNPs in the 
coding regions. Because 
there are hundreds of SNPs 
(since 65 to 1785) identified 
for each protein’s gene, we 
chose only those that are 
reported in the literature and 
those that play a possible 
role in aging and infectious, 
inflammatory, immunologi-
cal/autoimmune or neoplas-
tic disorders. By these crite-
ria we selected 74 SNPs 
(Tables 1 and 2).
Using the ‘HapMap’ following 
the methodology described 
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rs16958871
rs6493247
TAP1 chr6: 32,811,748-32,841,748 rs6457684 rs5019296
rs4148882 rs13199787
rs4148879 rs6457644
rs2127679 rs7773407
rs11758312
rs9276490
rs6918223
rs7770024
TAP2 chr6: 32,796,547-32,826,547 rs17583244 rs11758312
rs10484565 rs7773407
rs9380326 rs6457644
rs3819721 rs13199787
rs3819714 rs2859112
rs2857104 rs2395237
rs2228396 rs9461799
rs1800454 rs9469240
UBA52 Chr19: 18,662,614-18,692,614 rs3209501 rs10419226
rs6554 rs4808844
rs7256986
CUL5 Chr11: 107,859,408-107,889,408 rs7104942 rs11212672
rs12361570
ERAP1 chr5: 96,133,892-96,163,892 rs28366066 rs28096
rs17482078 rs1057569
rs1065407
rs149078
rs27042
rs469783
rs469758
rs26510
Table 2. SNPs in coding and promoter regions of selected 
genes from antigen processing/presentation systems (cont.)
Gene Gene location-pr SNPs-cr SNPs-pr
HLA-A chr6: 29,890,331-29,920,331 rs9260109 rs2523769
rs9260105 rs1077432
rs9260090 rs1318083
rs9260102 rs1610678
rs926100 rs1611165
rs2735113 rs1610682
rs2230954 rs407238
rs2735003
HLA-B chr6: 31,314,989-31,344,989 rs4997052 rs3868082
rs2596501 rs3132496
rs2523608 rs28480108
rs1140412 rs3134766
rs9264179
rs9264219
above for SNP selection for 
specific populations, we ch- 
ose those that exist in at 
least 20% of Caucasian pop-
ulations (this cut-off was also 
adequate for the relatively 
small size of our population 
sample) [12, 13]. The type of 
population and SNP frequen-
cy selection results in 56 
SNPs.
Of these SNPs, some were 
not compatible during pairing 
reactions and allele-specific 
extension oligonucleotides 
from PCR amplification in 
iPlexSequenom, MALDI-TOF. 
With this technical restric-
tion, 28 of 56 SNPs could be 
selected (Table 3).
Promoter regions
We applied the step-by-step 
strategy, previously descri- 
bed, to obtaining 26 SNPs.
We started by determining 
their exact promoter region 
using the Qiagen SABiosci- 
ence’s database. For exam-
ple the TAP1 gene promoter 
region has about 30 Kb and 
is located between the nucle-
otides from db 32,811,748 
and db 32,841,748 of chromo-
some 6 (Figure 1).
Then, we accessed ‘HapMap’ data-
base and searched SNPs located 
in the promoter region that was 
previously determined in the 
‘QIAGEN’ database. We retrieved 
440 SNPs from the promoter 
regions of the 22 proteins chosen. 
Then, we selected several SNPs 
whose minor allele frequency was 
above 20% [12, 13]. We observed 
approximately 10-30 SNPs per 
promoter, 0-14 of which fell within 
the criteria set out above. With 
these criteria, we selected 253 
SNPs for further study.
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rs3130427
rs1793891
rs2524119
rs2844626
rs2853961
rs2248902
rs2524099
rs1049281
HLA-C chr6: 31,229,855-31,259,855 rs13207315 rs1128175
rs13191343 rs885948
rs7773175 rs3094188
rs2395471 rs887466
rs2249742 rs3131018
rs2074488 rs1265155
rs9501066
HLA-E chr6: 30,437,271-30,467,271 rs1264457 rs3132628
rs1264459 rs3132626
rs3132622
rs3094623
rs3130133
rs6936943
rs3130139
rs3130144
rs1012411
rs2022082
rs2844746
rs3132644
rs3130362
rs2844745
HLA-F chr6: 29,671,117-29,701,117 rs17875380
rs9258170
rs2072895
rs1362126
HLA-G chr6: 29,774,756-29,804,756 rs12722477 rs7776082
rs9380142 rs9258122
rs2735022 rs3094727
rs1736936 rs2394660
rs1736935 rs3131863
rs1632949 rs1476572
rs1632947 rs1610586
rs1632933 rs1610594
rs915668 rs1611356
rs1710 rs1611381
Gene location-pr: gene location on promoter region; SNPs-cr: Selected SNPs 
of coding region; SNPs-pr: Selected SNPs of promoter region.
To understand which SNPs could 
potentially have greater impact on 
which TF binding to the promoter 
region, we used ‘Promoter TESS’ 
for functional analysis. With this 
software, we compared the TFs 
which bind to the sequence of the 
ancestral allele with TFs that bind 
to the sequence of the variant 
allele (that has the SNP). Because 
the usual length of TFBS is 6-12 bp 
[14], we searched ‘Promoter TESS’ 
using DNA sequences that includ-
ed the SNP and 10 nucleotides 
both the 5’ and 3’ directions. Thus, 
we identified 114 SNPs (from the 
previous 253) that could signifi-
cantly change the TFs that bind to 
the variant promoter region (Tables 
1 and 2).
Finally, we decided to search the 
literature for the role of these 
“new” TFs and select the SNPs for 
those which were related to aging 
and infectious, inflammatory, imm- 
unological/autoimmune and neo-
plastic disorders. Adopting this 
approach, we finally restricted our 
study to 87 SNPs located in the 
promoter regions (see the Su- 
pporting Information; Supplemen- 
tary File 1 shows the difference 
between the ancestral and variant 
nucleotide sequence and corre-
sponding TFs with affinity to them).
Similar to SNP selection from cod-
ing regions, some SNPs were not 
compatible in the iPlexSequenom 
MALDI-TOF platform, resulting in 
some technical, but not method-
ological, restriction to 26 SNPs 
(Table 3).
Considerations in selection criteria
The primary goal of this work was 
to try to understand the change in 
TF affinity induced by SNPs on DNA 
binding motifs of promoter regions. 
With this method it became possi-
ble to choose TFs and SNPs in an 
We identified the nucleotide sequence of 
ancestral and variant alleles of each SNP with 
the ‘dbSNP’ database and record this informa-
tion for using in the next steps.
oriented manner, permitting selection of those 
with a potential functional role.
Figure 2 provides a summary of all steps.
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Table 3. The final results in accordance with 
the methodology
Coding region Promoter region
rs17583244 rs4641136
rs7104942 rs11758312
rs2781003 rs16958871
rs12344615 rs1611356
rs10739575 rs7256986
rs3825172 rs17553775
rs706118 rs1766135
rs2228396 rs26510
rs12878391 rs4808844
rs2296840 rs2844745
rs9380326 rs28096
rs4148879 rs9461799
rs6924102 rs10139973
rs3209501 rs6457644
rs2281740 rs2787423
rs10484565 rs10419226
rs28366066 rs27042
rs2780995 rs7776082
rs3819721 rs7148603
rs6457684 rs469758
rs17875380 rs11205209
rs17336700 rs3132622
rs10760117 rs1766136
rs1632933 rs13199787
rs4148882 rs5019296
rs398606 rs1611381
rs1264457
rs1800454
Total: 54 SNPs
Discussion
This study describes methods for SNP search 
and selection that can be applied to any human 
gene. This is an empirical method to select 
functionally significant SNPs. The authors could 
not find in the medical literature a previous 
description of a practical approach to select 
SNPs in promoter regions based on their pre-
dictable functionality. The present method 
emphasizes the importance of promoter region, 
where the effects of the SNPs can be more 
complex than those of SNPs in the coding 
regions, even though its functional effect has a 
smaller impact. It compares the TFs with affini-
ty to the TFBS of the conserved ancestral 
sequence with the TFs that have affinity to the 
variant allele. Using this approach we were able 
to identify SNPs responsible for generating 
important differences in TFs pattern to a TFBS.
The authors identified and selected the SNPs 
that induced TFs active in NHL. Along the way, 
the applicability of the method was tested. For 
example, we studied the genes of the protein of 
several enzymatic systems involved in process-
ing and presentation of antigenic determinant.
The complexity found in transcription control 
and its multiple effects has been remarkable. 
Among several difficulties, we are faced with 
the promiscuity of the TFs. This phenomenon is 
possible because TFs can tolerate small differ-
ences in nucleotide sequences, although with 
different affinities. Another manifestation of 
tolerance in protein-DNA binding proprieties is 
the possibility of a DNA binding motif (TFBS), 
having affinity to multiple TFs albeit with differ-
ent binding energies. This last effect is called 
“degenerate consensus sequence”.
The TF affinity varies according to the 4 nucleo-
tide distribution in a particular sequence and 
has been defined by entropy-based mathemati-
cal models. Each position and type of nucleo-
tide in the TFBS features its own weight accord-
ing to its binding energy. A position weight 
matrix (PWM) is commonly used to represent 
this type of sequence motif [15]. The possible 
binding sequences can be identified using 
models and databases, such as MATCH and 
TESS, that use PWMs registered in JASPAR or 
TRANSFAC [10, 16-18].
The SNPs in the TFBS can introduce significant 
alterations in the type of TFs that bind there, 
eventually inducing changes in the gene tran-
scription. Recent studies by Michal et al led to 
the development of computer models that can 
estimate the result of replacing a base at the 
TFBS [19]. These predicted values for certain 
SNPs were compared with the published 
results, and a very good correlation was found. 
These studies need to be extensively done for 
all promoters in Homo Sapiens genes.
Although it is essential to understand the func-
tionality of a SNP in the regulating sequences, 
computational models of PWM and the meth-
odology developed in our work, do not solve the 
issue of the transcriptional control and gene 
expression. As described below, the TFBS can, 
and often are redundant in the promoter region. 
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Beyond its redundancy, its location and the 
effect of the “degenerate consensus sequence” 
also decrease functional impact of SNPs in reg-
ulatory regions. However, several associations 
between human diseases and these variations 
in the promoter binding sequences have been 
described, such as susceptibility for lupus, 
arthritis, HIV/AIDS, diabetes and heart disease. 
One of the most interesting findings regarding 
protection against HIV/AIDS is due to the poly-
morphism in the cis-regulatory region in the 
gene CCR5 that codes for CC chemokine recep-
tor 5, required for the HIV1 virus entrance into 
the cell [20].
To explore the effect of promiscuity/degenerate 
consensus sequence, we adopted an empirical 
approach to the genes of the proteins being 
studied, comparing the group of TFs that bind 
to conserved consensus motifs (ancestral 
allele) in the promoter regions with those that 
bind alternate sequence, where the SNP 
appeared (variant allele). Three possible sce-
narios occurred: 1) new TFs appeared with 
affinity to the new TFBS; 2) the usual TFs were 
kept due to the degenerate consensus sequ- 
ence; 3) an intermediate process such as small 
changes in the TFs, or the new TFs have low 
binding affinity for the new TFBS containing the 
SNP. In practical terms, SNP selection lies in 
those that induced significant alterations in the 
TF for the new sequence, that is, the ones that 
could potentially change the gene trans- 
cription.
There is an extensive complexity in the tran-
scriptional control currently known which 
accounted for some limitations of the study. For 
example, it did not consider factors that can 
influence the role of SNPs on the promoter 
regions, such as the number of repletion of 
TFBS for the same TF along the promoter 
region, their location, proximal or distal relative 
to the initiation site and the synergism between 
them. We can use the promoter region of TAP1 
located between 32,811,746 and 32,841,748 
Figure 1. ‘QIAGEN’ database reveals the promoter region and the TFs that bind to it. In this image, we can see that 
the promoter region of TAP1 gene is located between nucleotides 32,811,748 and 32,841,748 in chromosome 6. As 
represented, there are several TFs that can bind to this region and all TFs can bind to different binding sites in the 
promoter region. These are the concepts of “degenerate consensus sequence” and “promiscuity”.
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in chromosome 6 (chr6) as an example of 
degenerate consensus sequence and promis-
cuity shown in Figure 1. It has 9 binding sites 
for the transcription factor IRF-2. This TF has 
TFBS in >4000 genes: TAP1, GRAP2, CASP8, 
CIITA, CXCL11, DST, NF1, SPI1, TRIM63, and 
PRDM1 are the 10 most relevant that are 
involved in apoptosis, antigenic presentation 
and many other important processes in oncol-
ogy and immunology. On the other hand each 
TFBS can be the binding site for multiples TFs. 
The TFBS centered in the nucleotide 
32,811,824 is the binding site for IRF-1 and 
IRF-2, whereas the TFBS centered in the nucle-
otide 32,811,882 is the binding site for STAT1, 
STAT1α, and STAT1β.
The redundancy of TFBS and the phenomenon 
of binding entropy (degenerate consensus 
sequence) are not the only factor that modu-
lates transcriptional decision of TF. For exam-
ple, TFBS from promoter regions can be pres-
ent either in repressive or activator places. 
Even more important can be the TFBS location. 
Experimental studies, using reporter gene 
assays, found that time-conserved TFBS 
appear in the promoter proximal regions, close 
to the transcription start site and that muta-
Figure 2. Methodology of SNPs’ search in coding and promoter regions of the genes. Flowchart showing the steps 
used to find SNPs in coding region (left) and promoter region (right) and corresponding computer tools.
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tions in these TFBS had an important function-
al role. However, a considerable number of 
them were found 1 kb upstream already in the 
3’cis-regulatory promoter regions [21].
Although there are complexes mathematical 
models to determine PWM, few clinical models 
can predict alterations in the transcription deci-
sion with the introduction of an SNP in the TFBS 
nucleotide sequence. In the present study, the 
authors selected individual SNPs based on the 
differences of TFs affinity between the ances-
tral and the variant allele that potentially could 
have immediate clinical application.
TF selection should follow the clinician’s area of 
interest. Some groups have attempted to devel-
op methods to identify new entities and prog-
nostic groups of NHL and breast cancer based 
on tumor gene expression profiling that man-
dates the study of thousands of genes. This 
requires very expensive and sophisticated 
technology not available in most clinical set-
tings. The identification of several dominant TF 
would allow inferring the expression of a vast 
group of genes, i.e. genes containing the bind-
ing motifs for those TF [22]. We can imagine the 
replacement of the “tumor genetic profile” for 
the “tumor transcriptional profile” at a much 
lower cost.
Using our methodology we are currently study-
ing the selected SNPs in samples of patients 
with NHL and its role as etiologic risk factors as 
well as its prognostic value. 
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Supplementary File 1. The difference between the ancestral and variant nucleotide sequence (ac-
cording to the SNP which is in the 2nd column) and corresponding TFs with affinity to them
Gene SNPs (promoter region) Nucleotide region Transcription factors
Nucleotide region- 
Wild type
Transcription  
factors
PSMA6 rs1755784 CAAAGCCTTAGATGTTTTACT POU2F1/E12 CAAAGCCTTAAATGTTTTACT POU2F1
rs10139973 TTATCATGTAGCAAAAGACAT GATA-2 TTATCATGTAACAAAAGACAT E4BP4/TCF-4E
rs17553775 TCAATGGTGAGTTATAGTGAG AP-1/c-Myc/c-Fos TCAATGGTGACTTATAGTGAG --------
rs1766136 ATTTTCTTTCCCACTGTTTAA NP-TCII ATTTTCTTTCACACTGTTTAA --------
rs7148603 AGTGACCAAAGTAAGAATCTG LEF-1 AGTGACCAAAATAAGAATCTG c-Fos/c-Jun/AP-1
rs1766135 TGAATTCCCCTTTTCCCCCAA Pu box binding factor/ 
NF-Atc/NFAT-1
TGAATTCCCCCTTTCCCCCAA NP-TCII
rs2787423 CAGGTAGAGTGAGCTGGAAAG -------- CAGGTAGAGTAAGCTGGAAAG NP-TCII
rs1766143 CCCCCAAAAGGTATGTCCACC c-Rel/TEF-1 CCCCCAAAAGATATGTCCACC GATA-3
rs1766145 ATCAATTTTCTGGTAACTCCA c-Rel ATCAATTTTCAGGTAACTCCA AREB6
PSMB4 rs11205209 AGAAATATAAGATAAGGCAAG -------- AGAAATATAAAATAAGGCAAG NC-2
rs310133 ACCCCTTAACGACAACCATAA -------- ACCCCTTAACAACAACCATAA c-Myc
PSMD5 rs10985387 CAATGTGGACGCAGATGCATC E12/E47/ITF-2 CAATGTGGACACAGATGCATC E12/E47/ITF-2
rs10818593 TATACAAAATTGAGATTGCTT GATA-1 TATACAAAATCGAGATTGCTT GATA-1/POU2F1
rs4641136 CAGACTCGAGGGGCGTGCCAT Sp1 CAGACTCGAGAGGCGTGCCAT Sp1/p53
rs3802488 ACTTGAATCCGCCCTCCCCAG -------- ACTTGAATCCACCCTCCCCAG Sp1
rs13299463 AAGAGCTAACGAGAGTGGCCT c-Myb AAGAGCTAACAAGAGTGGCCT --------
rs4307413 CTTTGTGAAAGCCTGGATTTA C/EBPbeta CTTTGTGAAAACCTGGATTTA --------
PSMD9 rs4759415 AGCCTTGTCATGGCTGAGAAT -------- AGCCTTGTCACGGCTGAGAAT --------
PSMB8 rs28772340 CATAAGAGATTACATCCCCAT AP-2alphaB CATAAGAGATCACATCCCCAT c-Myc
rs2858892 GTAGTTCTTATACAACTGAAG c-Myc/c-Myb GTAGTTCTTACACAACTGAAG Zta
rs2859112 AGTGAGGCTTGGATGATGCCC Sp1 AGTGAGGCTTAGATGATGCCC --------
rs13199787 TTCATCAATGTATAAAATTAG NC2 TTCATCAATGCATAAAATTAG --------
rs7773407 CTGCAACCTCCAAAACCCTCT c-Ets2/c-Jun CTGCAACCTCAAAAACCCTCT NF-Gma/ELF-1
rs6457644 ACTGAACCCATGACTTCCCTT c-Ets2/c-Jun ACTGAACCCACGACTTCCCTT c-Ets2
rs11758312 GATTGGGTTGCTAAGAGAACT Zta/c-Myc GATTGGGTTGATAAGAGAACT c-Myc
rs9276490 GAATGCAACTGTAAAGAATGT c-Myc/c-Myb GAATGCAACTATAAAGAATGT --------
rs6918223 AGCTTGTCTGCCTTAATGACA -------- AGCTTGTCTGACTTAATGACA c-Jun
rs7770024 TGCACAGATGGAACTATAACA -------- TGCACAGATGAAACTATAACA E12/E47/ITF-2/Tal-1/ 
Tal1-beta
B2M rs16958856 TGTTATATTTTCTTCCATGAC -------- TGTTATATTTCCTTCCATGAC c-Ets2
rs4349090 CAATAAACAGGTGTGTGACTG AREB6 CAATAAACAGCTGTGTGACTG --------
rs16958871 GCAATAGTTATGTTGTAAAGT -------- GCAATAGTTACGTTGTAAAGT (C)EBPbeta
rs6493247 AAAAAATCCCGACAAGCTAGG -------- AAAAAATCCCAACAAGCTAGG (C)EBPbeta
TAP1 rs5019296 TGAGGCCAGGTGCAGTGGCTC AREB6/Lmo2 TGAGGCCAGGCGCAGTGGCTC AP-2alphaA/AP-2alphaB/ 
LBP-1
rs13199787 TTCATCAATGTATAAAATTAG NC2 TTCATCAATGCATAAAATTAG --------
rs6457644 ACTGAACCCATGACTTCCCTT c-Ets2/c-Jun ACTGAACCCACGACTTCCCTT c-Ets2
rs7773407 CTGCAACCTCCAAAACCCTCT NF-Gma CTGCAACCTCAAAAACCCTCT NF-Gma/ELF-1
rs11758312 GATTGGGTTGCTAAGAGAACT Zta/c-Myc GATTGGGTTGATAAGAGAACT c-Myc
rs9276490 GAATGCAACTGTAAAGAATGT c-Myb/c-Myc GAATGCAACTATAAAGAATGT --------
rs6918223 AGCTTGTCTGCCTTAATGACA -------- AGCTTGTCTGACTTAATGACA c-Jun 
rs7770024 TGCACAGATGGAACTATAACA -------- TGCACAGATGAAACTATAACA E12/E47/ITF-2/Tal-1/
Tal1-beta
TAP2 rs11758312 GATTGGGTTGCTAAGAGAACT Zta/c-Myc GATTGGGTTGATAAGAGAACT c-Myc
rs7773407 CTGCAACCTCCAAAACCCTCT c-Ets2/c-Jun CTGCAACCTCAAAAACCCTCT NF-GMA/ELF-1
rs6457644 ACTGAACCCATGACTTCCCTT NF-Gma ACTGAACCCACGACTTCCCTT c-Ets2
rs13199787 TTCATCAATGTATAAAATTAG NC2 TTCATCAATGCATAAAATTAG --------
rs2859112 AGTGAGGCTTGGATGATGCCC Sp1 AGTGAGGCTTAGATGATGCCC --------
rs2395237 GAAATAATAACGATAAGTTGT Cart-1/c-Myb GAAATAATAAAGATAAGTTGT Cart-1/TCF-1A
rs9461799 TCCCAATGGGTAACTGATTGC c-Myb TCCCAATGGGCAACTGATTGC c-Myb/c-Myc
rs9469240 GAGTGTGTAGTGAGATTGTTG p300/GATA-3 GAGTGTGTAGCGAGATTGTTG GATA-3
UBA52 rs10419226 AGTCACAAATTACCACAAAGT -------- AGTCACAAATGACCACAAAGT PEBP2beta
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rs4808844 CCGGGGCAGAGGGAGGAGCCT -------- CCGGGGCAGAAGGAGGAGCCT Sp1
rs7256986 TGTTTAAAACGGGAGCATAAC c-Myb TGTTTAAAACAGGAGCATAAC --------
CUL5 rs11212672 CTGGCAAACATGAAACAACTT c-Fos/c-Jun/Fra-1 CTGGCAAACACGAAACAACTT AP-2alphaA
rs12361570 AAATTCTTCTACGTCAACTTAG -------- AAATTCTTCTAAGTCAACTTAG c-Jun/c-Myb
ERAP1 rs28096 ACTGTATAGCGTCTGGCTTTA E47 ACTGTATAGCATCTGGCTTTA E47/E12/ITF-2/Tal-1beta
rs1057569 GTGGCAGCGGGGCAAGCAAAA POU2F2/E2F1 GTGGCAGCGGAGCAAGCAAAA --------
rs1065407 CTCCCTTGCCCGGTTCCTGTT ELF-1/c-Ets-1 CTCCCTTGCCAGGTTCCTGTT Pu.1/Elf-1
rs149078 AAAAAGCTACGAGACTGTAAC TCF-1 AAAAAGCTACAAGACTGTAAC LEF-1/TCF-1
rs27042 GTTTCATCACTTATTCATTGC GATA-3 GTTTCATCACCTATTCATTGC GATA-3/E4BP4
rs469783 TAATGAGACTTGCCCGATCAT Sp1/p53 TAATGAGACTCGCCCGATCAT p53
rs469758 ATTTGCTCCCTTGCCTGAAGA -------- ATTTGCTCCCCTGCCTGAAGA Pax5
rs26510 TAATCAAGGATCTCAGAAAGT -------- TAATCAAGGACCTCAGAAAGT E12
HLA-A rs2523769 GCCAAAGCAGTATTGTAAACT TCF-1 GCCAAAGCAGGATTGTAAACT --------
rs1077432 CATGTGATGGTTCATTTTCAA AP-1 CATGTGATGGCTCATTTTCAA Zta 
rs1318083 TTAAGACTTCTAGTATGTTCC TEF-1 TTAAGACTTCAAGTATGTTCC --------
rs1610678 TAGTTTTTTCGATAACTGGCT c-Myb TAGTTTTTTCAATAACTGGCT --------
rs1610682 AAATTCTCTTGTTATTTCTTT -------- AAATTCTCTTATTATTTCTTT c-Myc
rs407238 TGGGGAAGATGCTCTCTCACT c-Ets2 TGGGGAAGATCCTCTCTCACT --------
rs2735003 CCATACCAAACCCCTAGGTTC Sp1/AREB6 CCATACCAAAACCCTAGGTTC LBP-1
HLA-B rs3868082 TTGATTTTTATACATTTGGTT NC2 TTGATTTTTACACATTTGGTT Zta 
rs3132496 TTTCTAAGAACTGAGTGAATC c-Myb TTTCTAAGAAATGAGTGAATC --------
rs28480108 GACGGCTGCAGAAGTATCTTC NF-Gma GACGGCTGCAAAAGTATCTTC --------
rs3134766 ACACCATCACGCCTTACCCCT SP1/GATA-3 ACACCATCACACCTTACCCCT AREB6
rs9264179 GCATTTGAGTTCAGCCAGAGA -------- GCATTTGAGTCCAGCCAGAGA LBP-1
rs9264219 TGAGACTACTTCTGTTTTTGG -------- TGAGACTACTCCTGTTTTTGG Sp1
rs3130427 CTGAACCACAGTGCCCAGATA AML1/AML3 CTGAACCACAATGCCCAGATA AML1/AML3/SP1
rs1793891 AGGGACATGAGGTTCTGCTGC -------- AGGGACATGAAGTTCTGCTGC c-Myb
rs2524119 CAAAGGTCCCGCCTCTTAAAA Sp1 CAAAGGTCCCACCTCTTAAAA Sp1/AREB6
rs2844626 GACCAAGGACTGTACCTGGTA LBP-1 GACCAAGGACAGTACCTGGTA --------
rs2853961 ACTGTTGTTGTGGGAAGTCAA AML1c/c-Ets-2 ACTGTTGTTGCGGGAAGTCAA c-Ets-2
rs2248902 TTCTCCAAGAGGTGAGTGAGA AREB6 TTCTCCAAGAAGTGAGTGAGA --------
rs2524099 GAAACCTGATTGTGTGCTGCA POU2F1 GAAACCTGATCGTGTGCTGCA --------
rs1049281 GTCAATTCCTGGAAGTTGAGA -------- GTCAATTCCTAGAAGTTGAGA c-Myb
HLA-C rs1128175 ATAGCTAGAATGGAAAAAAGA NF-Atc/TCF-1A/NFAT-1 ATAGCTAGAACGGAAAAAAGA --------
rs885948 AGAAGGCAGATAGAGCCACTG GATA-3 AGAAGGCAGACAGAGCCACTG TCF-1
rs3094188 TTTTATGTCTTAGTTGGAAGG POU2F1/PEA3 TTTTATGTCTGAGTTGGAAGG PEA3
rs887466 TCTCCGGAAATACCTGAAAGC -------- TCTCCGGAAACACCTGAAAGC AREB6/c-Myc
rs3131018 GAACCAAGCATAGCTGCAGAA LEF-1 GAACCAAGCAGAGCTGCAGAA --------
rs1265155 CTGTGAGTTGTTGGGGAACCG AP-2alphaA/AP- 
2alphaB/(C)EBPbeta
CTGTGAGTTGCTGGGGAACCG AP-2alphaA/AP-2alphaB
rs9501066 GTGAAGTGGGGTGGTATCTGA Sp1 GTGAAGTGGGATGGTATCTGA Lmo2
HLA-E rs3132628 GGAATATATAGTTAGTTAAAA -------- GGAATATATAATTAGTTAAAA Sp1
rs3132626 ACTTACCAGGGAAACAACAAC -------- ACTTACCAGGAAAACAACAAC NFAT-1/Pu box binding 
factor
rs3132622 CAAGCTCTTTGAAAAATAACT -------- CAAGCTCTTTAAAAAATAACT TCF-1
rs3094623 TGCTGATCTATCTGTTCATGT GATA-3 TGCTGATCTACCTGTTCATGT --------
rs3130133 GAGGAGCCAGCTTCTTCTAAA -------- GAGGAGCCAGATTCTTCTAAA NF-Gma
rs6936943 ATCTGGGAAGGAAAAAAAAAA NF-AT1 ATCTGGGAAGAAAAAAAAAAA --------
rs3130139 TTAAAATTTCTGCTTCACATC -------- TTAAAATTTCCGCTTCACATC NP-TCII 
rs3130144 TCAAAAATTATAAAATAATTA -------- TCAAAAATTACAAAATAATTA E4BP4
rs1012411 GACAACTATGCCCTGTAGATG Sp1 GACAACTATGACCTGTAGATG --------
rs2022082 TGCAGCTACAGAGGCTCGGGG TCF-1 TGCAGCTACAAAGGCTCGGGG LEF-1/TCF-1
rs2844746 TACACAAGGTGAAAAGAGGAC AREB6 TACACAAGGTAAAAAGAGGAC --------
rs3132644 ATTGATAATGGTAATGTTGGC POU3F2/POU2F1 ATTGATAATGATAATGTTGGC POU2F1
rs3130362 TTGCCTATTCGTTTATTAGTT Pbx-1a TTGCCTATTCATTTATTAGTT POU3F2
rs2844745 ACCTTTATCCGTTAGATAAAA GATA-3 ACCTTTATCCATTAGATAAAA --------
HLA-G rs7776082 TGGCTTTACCGTTTTCCATTC c-Myb/Pu box binding 
factor
TGGCTTTACCATTTTCCATTC POU3F2
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rs9258122 TTTGCTGGGGTATAAATGTAA -------- TTTGCTGGGGCATAAATGTAA POU3F2
rs3094727 ATTTTCAGGTGTTGAATAGAA AREB6/c-Myc/E12 ATTTTCAGGTATTGAATAGAA c-Myb/ELF-1
rs2394660 AATTTCATGTGGCAGCTGTAA E12/HEB AATTTCATGTAGCAGCTGTAA E12
rs3131863 AGAGCAAGAGTGATGGACAGA Pbx-1a/Pbx-1b/NFAT-1 AGAGCAAGAGCGATGGACAGA NFAT-1
rs1476572 ATATCTACTGCAGGCCACAGC GATA-3/HEB ATATCTACTGAAGGCCACAGC GATA-3
rs1610586 AGAATGAACTGAGAGATACAC -------- AGAATGAACTAAGAGATACAC c-Myc 
rs1610594 CAGCCTCATTGTCCATCCTCT PEA3 CAGCCTCATTATCCATCCTCT Sp1
rs1611356 TTAGACATGAGTTAGTTGTCC c-Fos/E12 TTAGACATGACTTAGTTGTCC --------
rs1611381 GAATGGTAAATCAGCTTATTT POU3F2 GAATGGTAAACCAGCTTATTT LBP-1
rs1632957 CCACAAACCTTAGGATTACAG AREB6 CCACAAACCTCAGGATTACAG AML1a/E12
